ZNF839 Antibody

What is ZNF839 and why is it important to study?

ZNF839 (Zinc Finger Protein 839) is a member of the zinc finger protein family, which plays crucial roles in transcriptional regulation. While specific functions of ZNF839 are still being elucidated, zinc finger proteins generally bind to DNA and regulate gene expression. Studying ZNF839 can provide insights into gene regulation mechanisms, cell signaling pathways, and potentially disease mechanisms where transcriptional regulation is implicated. The molecular weight of ZNF839 is observed to be approximately 87 kDa, as determined by SDS-PAGE analysis .

What are the primary applications for ZNF839 antibodies in research?

ZNF839 antibodies are primarily used in Western Blotting (WB), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA), and Immunofluorescence/Immunocytochemistry (IF/ICC) . These techniques allow researchers to detect, quantify, and localize ZNF839 protein in various experimental contexts. The selection of application depends on your specific research question—whether you need to determine protein expression levels (WB), tissue localization patterns (IHC), protein-protein interactions, or subcellular localization (IF/ICC).

What species reactivity can I expect from commercially available ZNF839 antibodies?

Based on current commercial offerings, ZNF839 antibodies typically show reactivity to human ZNF839, with some antibodies also cross-reacting with rat and mouse orthologs . Some specific antibodies also demonstrate reactivity with cow and horse ZNF839 . Always verify the species reactivity information provided by the manufacturer for your specific research needs, especially when working with non-human models.

How should I determine the optimal antibody dilution for my ZNF839 Western blot experiments?

The optimal dilution for ZNF839 antibodies in Western blotting typically ranges from 1:500 to 1:5000, depending on the specific antibody preparation and target abundance . To determine the ideal dilution for your specific experimental conditions:

• Perform an antibody titration experiment using a sample known to express ZNF839

• Test a range of dilutions (e.g., 1:500, 1:1000, 1:2000, 1:5000)

• Select the dilution that provides the best signal-to-noise ratio

• Consider that polyclonal antibodies typically require less concentrated solutions compared to monoclonal antibodies

Always include positive and negative controls to validate specificity, and consider the expression level of your target protein in your specific samples.

What are the recommended protocols for immunohistochemistry with ZNF839 antibodies?

For optimal IHC results with ZNF839 antibodies, consider the following protocol recommendations:

• Tissue fixation and embedding: Standard formalin fixation and paraffin embedding is compatible with most ZNF839 antibodies

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective

• Blocking: 5-10% normal serum from the same species as the secondary antibody

• Primary antibody: Apply ZNF839 antibody at dilutions between 1:20 and 1:200

• Incubation: Overnight at 4°C or 1-2 hours at room temperature

• Detection: Standard HRP/DAB or fluorescence-based detection systems

As with all antibody applications, optimization for your specific tissue samples and experimental conditions is essential.

What controls should I include when using ZNF839 antibodies in my experiments?

Proper controls are critical for ensuring reliability and interpretability of results with ZNF839 antibodies:

Including these controls helps distinguish true signals from artifacts and validates antibody specificity.

I'm experiencing high background in my Western blots with ZNF839 antibody. What are possible causes and solutions?

High background in Western blots can be caused by multiple factors. Here are potential solutions specific to ZNF839 antibody applications:

• Antibody concentration: The recommended dilution range for Western blotting is 1:500 to 1:2000 . Try using a more dilute antibody solution.

• Blocking optimization: Increase blocking time or try alternative blocking agents (BSA vs. milk).

• Wash conditions: Increase number and duration of washes with TBST or PBST.

• Secondary antibody: Ensure secondary antibody is properly diluted (typically 1:5000 to 1:10000).

• Storage conditions: Confirm the antibody has been stored properly at -20°C and hasn't undergone multiple freeze-thaw cycles.

• Buffer composition: The antibody is typically supplied in PBS with sodium azide and glycerol . Ensure compatibility with your experimental buffers.

If high background persists, consider further optimization of blocking conditions or changing detection methods.

Why might I be detecting multiple bands in my Western blot with ZNF839 antibody?

Multiple bands in ZNF839 Western blots could arise from several sources:

• Post-translational modifications: ZNF839 may undergo phosphorylation, SUMOylation, or other modifications that alter migration patterns.

• Splice variants: Alternative splicing may generate different ZNF839 isoforms.

• Protein degradation: Sample preparation or storage issues can lead to degradation products.

• Cross-reactivity: Polyclonal ZNF839 antibodies may recognize related zinc finger proteins due to conserved domains.

• Non-specific binding: Particularly if the additional bands don't correspond to predicted molecular weights of modified forms or fragments.

To address this issue:

• Compare observed bands with predicted molecular weights (the main ZNF839 band is approximately 87 kDa)

• Use fresh samples with protease inhibitors

• Validate results with alternative ZNF839 antibodies targeting different epitopes

• Consider enrichment methods (immunoprecipitation) to confirm identity of bands

My immunohistochemistry with ZNF839 antibody shows weak or no staining. How can I improve signal intensity?

For improved IHC signal with ZNF839 antibodies, consider these approaches:

• Antigen retrieval optimization: Test different retrieval methods (heat vs. enzymatic) and buffer compositions (citrate vs. EDTA).

• Antibody concentration: Try a more concentrated antibody dilution within the recommended range of 1:20 to 1:200 .

• Incubation conditions: Extend primary antibody incubation time (overnight at 4°C) or optimize temperature.

• Detection system sensitivity: Switch to a more sensitive detection system, such as tyramide signal amplification.

• Sample fixation: Overfixation can mask epitopes; consider testing different fixation protocols.

• Endogenous enzyme blocking: Ensure complete quenching of endogenous peroxidase or phosphatase activity.

If these approaches don't improve results, the target may be expressed at low levels in your samples, or the epitope might be altered or inaccessible.

How can I validate the specificity of ZNF839 antibody in my cellular system?

Validating antibody specificity is critical for reliable research outcomes. For ZNF839 antibodies, consider these validation approaches:

• Genetic approaches:

  • siRNA/shRNA knockdown of ZNF839 followed by Western blot to confirm signal reduction

  • CRISPR/Cas9 knockout of ZNF839 as a definitive negative control

  • Overexpression of tagged ZNF839 to confirm co-localization with antibody signal

• Biochemical approaches:

  • Immunoprecipitation followed by mass spectrometry to confirm identity

  • Peptide competition assays using the immunizing peptide (typically from the center region of human ZNF839)

  • Testing multiple antibodies targeting different epitopes of ZNF839

• Comparative analysis:

  • Correlation of antibody signal with mRNA expression across tissues or cell lines

  • Comparison of subcellular localization with predicted localization based on protein domains

These validation approaches provide complementary evidence for antibody specificity.

Can ZNF839 antibodies be used for chromatin immunoprecipitation (ChIP) experiments?

While the search results don't specifically mention ChIP applications for ZNF839 antibodies, this approach is theoretically feasible given that:

• ZNF839 is a zinc finger protein likely involved in DNA binding and transcriptional regulation

• The available antibodies are polyclonal and purified by affinity chromatography , which often makes them suitable for immunoprecipitation applications

For optimizing ChIP with ZNF839 antibodies:

• Start with antibodies validated for immunoprecipitation

• Use crosslinking conditions optimized for transcription factors

• Include appropriate controls (input DNA, IgG control, positive control with known transcription factor)

• Validate ChIP efficiency with qPCR for predicted binding sites before proceeding to ChIP-seq

• Consider dual crosslinking approaches if standard formaldehyde crosslinking yields poor results

Since this is not a validated application in the provided information, extensive optimization and validation would be required.

What is known about the functional domains of ZNF839 and how might this inform antibody selection?

While the search results don't provide detailed information on ZNF839 functional domains, we can infer from related zinc finger proteins and antibody targeting information:

• As a zinc finger protein, ZNF839 likely contains:

  • DNA-binding zinc finger domains

  • Possibly a KRAB (Krüppel-associated box) domain, which is common in zinc finger proteins and mediates transcriptional repression (by analogy with ZNF283 mentioned in result )

  • Nuclear localization signals

• The available antibodies target:

  • "Center region" of human ZNF839

  • "Internal region" and "Middle region" epitopes

  • Specific amino acid regions (e.g., AA 530-579)

When selecting antibodies for specific applications:

• For protein detection in denaturing conditions (WB), antibodies targeting linear epitopes in any domain may work

• For applications involving native protein (IP, ChIP), consider antibodies targeting accessible regions outside DNA-binding domains

• For functional studies, antibodies targeting known functional domains might interfere with protein activity

A comprehensive domain analysis would require additional protein structure information not provided in the search results.

How should I quantify and normalize Western blot data for ZNF839?

For accurate quantification of ZNF839 in Western blots:

• Image acquisition:

  • Capture images within the linear dynamic range of your detection system

  • Avoid saturated pixels that will underestimate expression differences

• Quantification approach:

  • Use densitometry software (ImageJ, Image Lab, etc.) to measure band intensity

  • Subtract local background from each measurement

• Normalization strategies:

  • Normalize to loading controls like GAPDH , β-actin , or total protein staining (Ponceau, SYPRO Ruby)

  • When comparing across multiple blots, include a common reference sample on each blot

• Statistical analysis:

  • Run samples in biological replicates (minimum n=3)

  • Apply appropriate statistical tests based on your experimental design

  • Report both normalized values and statistical significance

Remember that Western blotting is semi-quantitative, and major expression differences should be validated by complementary methods.

How do I interpret subcellular localization patterns of ZNF839 in immunofluorescence experiments?

ZNF839, as a zinc finger protein, is expected to function primarily as a transcription factor. When interpreting immunofluorescence results:

• Expected localization:

  • Primary localization should be nuclear, potentially with nucleolar exclusion

  • Some cytoplasmic localization might occur depending on cell state or regulation

• Potential localization patterns and their interpretation:

  • Exclusive nuclear localization: Consistent with transcriptional regulatory function

  • Nuclear speckles or foci: May indicate association with specific chromosomal regions or transcriptional complexes

  • Nucleocytoplasmic distribution: Could suggest regulated nuclear import/export

  • Unexpected patterns (e.g., exclusively cytoplasmic): May indicate antibody cross-reactivity or novel functions

• Validation approaches:

  • Co-stain with nuclear markers (DAPI, Hoechst)

  • Compare with other zinc finger proteins

  • Validate unusual patterns with epitope-tagged constructs

The specific localization pattern may provide clues to ZNF839 function beyond what is currently documented in the literature.

Are there any known post-translational modifications of ZNF839 that might affect antibody recognition?

• Potential PTMs in zinc finger proteins:

  • Phosphorylation (especially on serine and threonine residues)

  • SUMOylation (often modulating transcriptional activity)

  • Ubiquitination (regulating protein stability)

  • Acetylation (affecting DNA binding or protein interactions)

• Impact on antibody detection:

  • PTMs may mask epitopes or create new ones

  • Modified protein may migrate differently in SDS-PAGE

  • PTMs might be cell type or condition-specific

• Strategies to address PTM concerns:

  • Use antibodies targeting different regions of ZNF839

  • Consider phosphatase or deubiquitinase treatment of samples

  • Compare results across different cell states or treatments

Researchers interested in specific PTMs of ZNF839 may need to conduct dedicated proteomic analyses, as this information appears to be limited in current literature.

How might I investigate potential protein-protein interactions involving ZNF839?

To investigate ZNF839 interaction partners, consider these methodological approaches:

• Co-immunoprecipitation (Co-IP) strategies:

  • Use purified ZNF839 antibodies for IP followed by mass spectrometry

  • Validate key interactions with reverse Co-IP

  • Consider crosslinking approaches for transient interactions

• Proximity-based methods:

  • BioID or TurboID fusion proteins to identify proximal proteins

  • FRET or BRET assays for direct interaction with suspected partners

  • Proximity ligation assay (PLA) for endogenous protein interactions

• Functional interaction screens:

  • Y2H (yeast two-hybrid) or mammalian two-hybrid screens

  • Genetic interaction screens (e.g., synthetic lethality approaches)

  • Correlation analysis of gene expression patterns

• Computational predictions:

  • Domain-based interaction predictions

  • Co-evolution analysis

  • Literature mining for interactions with related zinc finger proteins

By combining multiple approaches, researchers can build confidence in identified interaction partners and begin to construct functional networks involving ZNF839.

What considerations should be taken when comparing results from different ZNF839 antibodies?

When using multiple ZNF839 antibodies in research, consider these important factors:

• Epitope differences:

  • Antibodies targeting different regions of ZNF839 may yield different results

  • Some available antibodies target the internal/middle region , while others target specific amino acid sequences (e.g., AA 530-579)

  • Epitope accessibility may vary depending on protein conformation or interactions

• Antibody format and performance characteristics:

  • Polyclonal vs. monoclonal (all described ZNF839 antibodies in the search results are polyclonal)

  • Production host (rabbit or mouse)

  • Purification method (affinity chromatography)

  • Validated applications (some for WB only, others for multiple applications)

• Reconciling discrepant results:

  • Validate with orthogonal methods (mRNA expression, tagged constructs)

  • Consider that different antibodies may recognize different isoforms or modified forms

  • Evaluate each antibody's validation evidence critically

• Reporting practices:

  • Document catalog numbers and lot numbers in publications

  • Specify dilutions and conditions used

  • Share validation data when publishing novel findings

What are the optimal storage conditions for ZNF839 antibodies to maintain activity?

For maximum longevity and performance of ZNF839 antibodies:

• Storage temperature:

  • Store at -20°C for long-term preservation

  • Avoid storing at 4°C for extended periods

• Aliquoting recommendations:

  • Upon receipt, divide antibody into small, single-use aliquots

  • This minimizes freeze-thaw cycles that can degrade antibody activity

  • Use sterile conditions when preparing aliquots

• Freeze-thaw considerations:

  • Minimize freeze-thaw cycles; each cycle can reduce activity

  • Thaw antibody aliquots on ice before use

  • Do not vortex antibody solutions; mix gently by pipetting or flicking

• Buffer composition:

  • ZNF839 antibodies are typically supplied in buffer containing:

    • PBS or potassium phosphate (0.42%)

    • Sodium chloride (0.87%)

    • Glycerol (30-50%) as cryoprotectant

    • Sodium azide (0.01-0.02%) as preservative

  • These components help maintain antibody stability

• Working solution handling:

  • Diluted working solutions are less stable than stock

  • Prepare fresh working dilutions when possible

  • If storing diluted antibody, use at 4°C within 1-2 weeks with proper preservative

Proper storage and handling are essential for maintaining antibody performance throughout your research project.

How might CRISPR-based approaches be combined with ZNF839 antibodies for functional studies?

CRISPR technology offers powerful approaches for studying ZNF839 function when combined with antibody-based detection:

• Validation applications:

  • CRISPR knockout of ZNF839 provides the ultimate negative control for antibody specificity

  • CRISPR-mediated tagging of endogenous ZNF839 allows correlation of tag and antibody signals

• Functional genomics approaches:

  • CRISPR knockout followed by phenotypic analysis and rescue experiments

  • ChIP-seq with ZNF839 antibodies before and after perturbation of potential regulators

  • CRISPR screening to identify genes that modify ZNF839 expression or localization

• Structure-function analysis:

  • CRISPR-mediated domain deletions or mutations combined with antibody detection

  • Analysis of recruitment to specific genomic loci after domain perturbation

• Methodological considerations:

  • Verify CRISPR editing efficiency using the ZNF839 antibody

  • Consider the timing of analyses relative to CRISPR editing (acute vs. stable perturbation)

  • Account for potential compensatory mechanisms in stable knockout lines

These approaches can provide mechanistic insights beyond what is possible with either technique alone.

Based on studies of other zinc finger proteins, what potential functions might ZNF839 have?

While specific ZNF839 functions aren't detailed in the search results, insights from related proteins like ZNF283 suggest potential roles:

• Transcriptional regulation:

  • Most zinc finger proteins function as transcription factors

  • May act as activators or repressors depending on interacting partners

  • Likely bind specific DNA sequences via zinc finger domains

• Immune response regulation:

  • ZNF283 was shown to be upregulated during viral infection and impeded virus production

  • ZNF839 might similarly participate in host defense mechanisms

  • Could regulate expression of immune-related genes

• Development and differentiation:

  • Many zinc finger proteins regulate developmental processes

  • May control cell fate decisions or tissue-specific gene expression

  • Could have temporal specificity during embryonic or adult development

• Potential research directions:

  • Identify DNA binding motifs using ChIP-seq with ZNF839 antibodies

  • Analyze expression patterns across tissues and developmental stages

  • Examine responses to various cellular stresses or stimuli

  • Investigate potential roles in disease processes where gene regulation is altered

Studies of ZNF839 could reveal novel regulatory mechanisms in one or more of these functional domains.

What are the considerations for using ZNF839 antibodies in multiplex immunofluorescence applications?

For researchers planning multiplex detection including ZNF839:

• Antibody compatibility factors:

  • Host species considerations: Available ZNF839 antibodies are primarily rabbit polyclonal , requiring careful selection of other antibodies to avoid cross-reactivity

  • ZNF839 antibodies are typically unconjugated , allowing flexibility in secondary detection systems

• Protocol optimization for multiplex detection:

  • Sequential immunostaining may be preferable to simultaneous for some applications

  • Antibody stripping or quenching between rounds may be necessary

  • Consider tyramide signal amplification for weak signals

• Spectral considerations:

  • ZNF839 is expected to have nuclear localization; pair with markers in other subcellular compartments for easier discrimination

  • Account for potential autofluorescence of tissues, particularly when using shorter wavelength fluorophores

• Controls for multiplex applications:

  • Single-stain controls are essential for assessing bleed-through

  • Include absorption controls when using multiple antibodies from the same species

• Analysis approaches:

  • Consider spectral unmixing for closely overlapping fluorophores

  • Quantitative colocalization analysis may reveal functional relationships